Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.63 |
| ▸ | PDE4A | P27815 | 14/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713621 | 0.84 | ADORA2B (0.58) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1713671 | 0.82 | ADORA3 (0.59) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1713372 | 0.80 | ADORA2B (0.66) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1713057 | 0.79 | ADORA2B (0.40) | ADORA2BADORA2AADORA3 | |
| SCHEMBL1712883 | 0.79 | ADORA2B (0.64) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7744388 | 0.79 | ADORA2B (0.97) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1712819 | 0.79 | ADORA2B (0.52) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1712892 | 0.78 | ADORA2B (0.39) | ADORA2BADORA2AADORA3 | |
| SCHEMBL12462314 | 0.78 | ADORA2B (0.39) | ADORA2BADORA2AADORA3 | |
| SCHEMBL21381240 | 0.78 | ADORA2B (0.94) | ADORA2BPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7863285-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863285-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863285-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2049544-B1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-2049544-B1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885PDE4A 158/4885PDE4B 333/4885 |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885PDE4A 158/4885PDE4B 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.